Table 6.
Clinically Effective PG Treatment: Injectables and Other Options
| Author | Year | LOE | Patients (n) | Age (y) | Areas Affected | Treatment Type | Resolution after 1 Session | Sessions to Resolve | Last Follow-up (m) | Complications |
|---|---|---|---|---|---|---|---|---|---|---|
| Matsumoto et al79 | 2001 | III | 9 | 25.2 | Head/neck, oral cavity | Sclerotherapy, monoethanolamide oleate | 100% | 1 | 3 | Pain during injection, postinflammatory pigmentation |
| Ichimiya et al80 | 2004 | III | 5 | 38.2 | Head/neck, digits | Ethanol injection | 100% | 1 | 1 | Pain and swelling |
| Ghodsi et al81 | 2006 | I | 76 | 34.8 | Cutaneous or labial | Cryotherapy/liquid nitrogen | 63% | 1.42 | 4 | Scaring, dyspigmentation |
| Curettage and electrodesiccation | 97% | 1.03 | ||||||||
| Shivhare et al82 | 2022 | III | 73 | 36.9 | Oral cavity | Diode Laser | 81.3% | 1 | 3 | Pain, edema, ulceration, ecchymosis, infections, and scarring |
| Sclerotherapy 3% sodium tetradecyl sulfate | 16.6% | >1 | ||||||||
| Yang et al83 | 2023 | III | 11 | 14.8 | Head/neck, trunk, extremities | Sclerotherapy, polidocanol | 73% | 1.45 | 6 | Swelling, fever, skin rash, and red rash |